Results 61 to 70 of about 5,420 (200)

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

HIV/AIDS: Research and Palliative Care, 2012
Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31Médecins Sans Frontières, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease
Lee JSF, Calmy A, Andrieux-Meyer I, Ford N   +3 more
doaj  

Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages

Biochemistry and Biophysics Reports, 2017
Purpose: Monocytes serve as sanctuary sites for HIV-1 from which virus is difficult to be eliminated. Therefore, an effective viral suppression in monocytes is critical for effective antiretroviral therapy (ART).
Yuqing Gong, Pallabita Chowdhury, Narasimha M. Midde, Mohammad A. Rahman, Murali M. Yallapu, Santosh Kumar   +5 more
doaj   +1 more source

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

Open Forum Infectious Diseases
TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)–based regimens.
M. Ait-Khaled, J. Oyee, Adrian Yit Reen Ooi, B. Wynne, A. Maldonado, B. Jones, Tao Wang   +6 more
semanticscholar   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Formulation development of dual-compartment topical inserts combining Tenofovir Alafenamide and Elvitegravir for flexible on-demand HIV prevention.

Journal of Controlled Release
Pre-exposure prophylaxis (PrEP) has emerged as a prominent approach for the prevention of HIV infections. While the latest advances have resulted in effective oral and injectable product options, there are still gaps in on-demand, event-driven, topical ...
V. Agrahari, M. Peet, N. Chandra, Prakash Ramalingam, Pardeep K. Gupta, S. Jonnalagadda, Onkar N. Singh, Timothy J. McCormick, Gustavo F. Doncel, M. Clark   +9 more
semanticscholar   +1 more source

Multiple choices for HIV therapy with integrase strand transfer inhibitors

Retrovirology, 2012
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several
Raffi Francois, Wainberg Mark A
doaj   +1 more source

Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. [PDF]

PLoS ONE, 2013
Our objective is to create gene immunogens targeted against drug-resistant HIV-1, focusing on HIV-1 enzymes as critical components in viral replication and drug resistance. Consensus-based gene vaccines are specifically fit for variable pathogens such as
Olga Krotova, Elizaveta Starodubova, Stefan Petkov, Linda Kostic, Julia Agapkina, David Hallengärd, Alecia Viklund, Oleg Latyshev, Eva Gelius, Tomas Dillenbeck, Vadim Karpov, Marina Gottikh, Igor M Belyakov, Vladimir Lukashov, Maria G Isaguliants   +14 more
doaj   +1 more source

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, Volume 27, Issue 5, Page 761-770, May 2026.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source